CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment.
about
Cerebrospinal fluid biomarkers of Alzheimer’s diseaseExploring Biomarkers for Alzheimer's DiseaseBiomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.Human body fluid proteome analysis.Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patientsSaliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study.Probable early-onset Alzheimer's disease in an apolipoprotein E2 homozygoteMass spectrometric analysis of rat cerebrospinal fluid proteins following exposure to the neurotoxicant carbonyl sulfide.Identifying and validating biomarkers for Alzheimer's disease.Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease.The influence of cerebrospinal fluid (CSF) biomarkers on clinical dementia evaluationsPlatelet-derived secreted amyloid-precursor protein-β as a marker for diagnosing Alzheimer's disease.Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-studyCSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer's Disease Patients from Healthy SubjectsPlatelet dysfunction in hypercholesterolemia mice, two Alzheimer's disease mouse models and in human patients with Alzheimer's disease.An integrated microfluidic chip for immunocapture, preconcentration and separation of β-amyloid peptides.Fluid biomarkers in Alzheimer disease.How proteomics reveals potential biomarkers in brain diseases.Biomarkers for amyotrophic lateral sclerosis.The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's diseaseBiomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?Targeted proteomics in Alzheimer's disease: focus on amyloid-beta.Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases.Proteomics of human neurodegenerative diseasesA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.Targeted Metabolomic Analysis of Soluble Lysates from Platelets of Patients with Mild Cognitive Impairment and Alzheimer's Disease Compared to Healthy Controls: Is PC aeC40:4 a Promising Diagnostic Tool?Tau as a biomarker of neurodegenerative diseases.Proteomic Analysis of Protein Expression Throughout Disease Progression in a Mouse Model of Alzheimer's Disease.Computational integration of nanoscale physical biomarkers and cognitive assessments for Alzheimer's disease diagnosis and prognosis.Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1-42 levels.Still debating a cause and diagnostic criteria for Alzheimer's disease.Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer's disease.Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound.Conformationally altered p53: a novel Alzheimer's disease marker?An Artificial Neural Network Integrated Pipeline for Biomarker Discovery Using Alzheimer's Disease as a Case Study.
P2860
Q22252572-39286BD2-9C99-4863-A082-041587638547Q28079218-BFA31FB4-93A5-458A-BD5C-C94EA05662BEQ30651551-B8F855EA-FC49-4271-A1B5-AAEC3FD81092Q33262623-FAD58D9F-52CA-4716-9113-BEC681166B13Q33448926-814FEE33-0212-4002-A9FA-91AC87EAA8D1Q33737093-90FAC33F-EF2B-487C-8F20-0BAB36B9CA08Q34354478-B6A30158-8452-495D-9990-75BC49F70862Q34453057-5DC2ED1B-9B7F-4FB4-AAF8-D30096504BE3Q34468961-ED3C8878-9F45-4950-A35F-84E56C1A1ADBQ34610487-64BAFAC8-1F0D-46C2-84B8-AF832FE5BD98Q34873817-82D3CD2F-C9F8-43B4-BC36-FB3461F2AC33Q35029908-56A496D5-1596-4063-B4D1-6CFD8471AA13Q35034827-561F492B-C197-4FD0-9743-BD0B36C6FEB1Q35114771-D5679806-5E4F-49F6-8F9B-DC973EC7F864Q35607653-403C0574-8283-450C-9622-9E824CCABF71Q35804607-A05AC329-6E0F-441B-8236-3EC7424D8DA0Q36117914-CA4AAF80-F49E-4183-ADBC-3E5576DDE4A9Q36186513-9AD0807C-E89D-463A-B570-F5E6CDE4B51DQ36322155-E5CD1F99-BC64-4503-94A6-2747DEDC7C8CQ36481118-110B29D0-CEB1-4C9D-B0C9-61B157DFFC62Q37054759-F3DA89FC-B846-45B7-A816-FDBC7CF8A368Q37118083-9F4056F5-DA12-47C7-9D7A-4F16F080518AQ37157835-65524FF1-2E64-4090-8A9F-52CF5E2B68CCQ37206262-2303B36B-AB2E-4B3F-935E-D6ED056A8258Q37260477-5BC355A6-C6BA-48C3-A1FC-E666A797BDF4Q37465017-A3C1FDD0-521A-487C-83D3-E4F7CCB1677BQ38222874-3AE1FABE-FD85-4D5F-99A1-83B78718C587Q38344088-3D1A7646-673D-417E-B9FF-DD2C88902745Q38922839-C8E2A133-E0E3-42E3-A3BE-9382C0401F46Q40065021-8267B9B7-E8D9-47DC-862F-F221E2E10B12Q41325309-4BC8A8D3-3A5B-4FDA-8823-671988B81AB5Q41845239-E90364B1-D5C8-4537-8863-C7C4FC8D6EA1Q41898767-FA026E90-158D-40C4-80CC-7AA539283082Q42618318-A48B0642-9BE0-4839-8D32-8EBD05666282Q47107001-21CAF48B-39ED-4DC4-8850-510DB85CE772Q50559392-E3380D10-02E3-44E3-94EF-4F29486411AFQ51900746-B817E6A4-4444-49CD-9D2E-E6C4A9F6E7E3Q55488983-48CE48D8-1C8A-40E3-B1AE-05C9F3B978EC
P2860
CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
CSF biomarkers for Alzheimer's ...... evaluation of drug treatment.
@ast
CSF biomarkers for Alzheimer's ...... evaluation of drug treatment.
@en
type
label
CSF biomarkers for Alzheimer's ...... evaluation of drug treatment.
@ast
CSF biomarkers for Alzheimer's ...... evaluation of drug treatment.
@en
prefLabel
CSF biomarkers for Alzheimer's ...... evaluation of drug treatment.
@ast
CSF biomarkers for Alzheimer's ...... evaluation of drug treatment.
@en
P2860
P356
P1476
CSF biomarkers for Alzheimer's ...... evaluation of drug treatment.
@en
P2860
P304
P356
10.1586/14737159.5.5.661
P50
P577
2005-09-01T00:00:00Z